Dyslipidemia Incidence in Atopic Dermatitis Patients Treated With Oral Janus Kinase Inhibitors: A Real-World Retrospective Study

Abstract

Keywords

abrocitinib upadacitinib JAK inhibitors Janus kinase inhibitors dyslipidemia

Get full access to this article

View all access options for this article.

References

Lee

Plante

Korte

, et al. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: a systematic review and meta-analysis. Skin Health Dis. 2022;3(1):e133. doi:10.1002/ski2.133

Pearson

Thanassoulis

Anderson

, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016

Davis

DMR

Drucker

Alikhan

, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102

Kim

Seo

Koopman

JJE

Yee

. Real-world effectiveness and safety of JAK inhibitors in atopic dermatitis: a systematic review and meta-analysis. Clin Exp Allergy. 2025;55(9):755-772. doi:10.1111/cea.70125

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

2.80 MB